Pharmacology, Toxicology and Pharmaceutical Science
Ribavirin
66%
Hepatitis C
37%
Infection
37%
Sofosbuvir
37%
Placebo
37%
Adverse Event
36%
Hepatitis C Virus
34%
Liver Cirrhosis
31%
Chronic Hepatitis C
30%
Antivirus Agent
29%
Nonalcoholic Fatty Liver
27%
Peginterferon
26%
Hepatitis C Virus Genotype 1
25%
Fibrosis
22%
Virus RNA
19%
Pharmacokinetics
19%
Interferon
15%
Daclatasvir
13%
Boceprevir
12%
RNA
10%
Antiviral Activity
10%
Clinical Trial
9%
Monotherapy
9%
Blindness
9%
Ledipasvir Plus Sofosbuvir
9%
Simeprevir
8%
Ledipasvir
8%
Drug
8%
Nonstructural Protein 5A Inhibitor
8%
Proteinase Inhibitor
7%
Telaprevir
7%
Deterioration
7%
Peginterferon Alpha2a
7%
Velpatasvir
7%
Tolerability
7%
Ritonavir
6%
Vaniprevir
5%
Headache
5%
Fatigue
5%
Medicine and Dentistry
Patient
100%
Therapeutic Procedure
48%
Inpatient
35%
Nonalcoholic Fatty Liver
33%
Fibrosis
23%
Ribavirin
21%
Combination Therapy
17%
Liver Cirrhosis
16%
Genotype
14%
Hepatitis C Virus
12%
Chronic Hepatitis C
12%
Hepatitis C
12%
Infection
12%
Placebo
12%
Antivirus Agent
11%
Peginterferon
11%
Sofosbuvir
10%
Adverse Event
9%
Liver
8%
Clinical Trial
7%
Hepatitis C Virus Genotype 1
7%
Analysis
6%
Interferon
5%
Arm
5%
Liver Fibrosis
5%
Follow up
5%
Nursing and Health Professions
Patient
39%
Ribavirin
28%
Sustained Virologic Response
17%
Inpatient
13%
Peginterferon
12%
Combination Therapy
11%
Liver Cirrhosis
10%
Hepatitis C
10%
Chronic Hepatitis C
9%
Infection
8%
Sofosbuvir
7%
Patient-Reported Outcome
6%
Telaprevir
6%
Nonalcoholic Fatty Liver
6%
Analysis
6%
Confidence Interval
5%
Fibrosis
5%
Adverse Event
5%
Procedures
5%
